NCT03539055View on ClinicalTrials.gov

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

February 29, 2024

Conditions
Atrial FibrillationDevice Related ThrombusLeft Atrial Appendage ThrombosisWatchman LAA Closure Device
Interventions
DRUG

Dabigatran Etexilate Oral Capsule

Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER

NCT03539055 - Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). | Biotech Hunter | Biotech Hunter